dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Ch, F. Tolis | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Sourla, A. | en |
dc.contributor.author | Klouvas, G. D. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Ch, F. Tolis | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Sourla, A. | en |
dc.creator | Klouvas, G. D. | en |
dc.date.accessioned | 2018-06-22T09:54:21Z | |
dc.date.available | 2018-06-22T09:54:21Z | |
dc.date.issued | 1991 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42318 | |
dc.description.abstract | In a pilot phase II study we have treated 25 patients with small cell lung cancer by utilizing 3 non-cross resistant drug regimens given in a sequential fashion in combination with radiotherapy to the primary tumor. VAC regimen (etoposide, doxorubicin, cyclophosphamide) was planned to induce major cytotoxity, CVM (cisplatin, vincristin, high-dose methotrexate) to intensify cell killing and MCP (mitomycin-C, CCNU, procarbazine) to maintain response. Overall response rate was 88% with 24% complete and 64% partial responders. Duration of response was 8.3+ months. Median survival was 12 months, 17 for complete and 10.5 months for partial responders. Sixty-one per cent survived for more than one year, while one patient is alive with no evidence of disease 30 months after diagnosis. In conclusion, sequential chemotherapy with non-cross resistant cytostatic agents in small cell lung cancer did not offer superior results compared to any other form of treatment. © 1991. | en |
dc.language.iso | eng | en |
dc.source | Lung Cancer | en |
dc.subject | Article | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Procarbazine | en |
dc.subject | Vincristine | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Clinical article | en |
dc.subject | Drug resistance | en |
dc.subject | Neurotoxicity | en |
dc.subject | Survival | en |
dc.subject | Lung small cell cancer | en |
dc.subject | Lomustine | en |
dc.subject | Male | en |
dc.subject | Gastrointestinal symptom | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Mitomycin c | en |
dc.subject | Oral drug administration | en |
dc.subject | Small cell lung cancer | en |
dc.subject | Sequential non-cross resistant chemotherapy | en |
dc.title | No response or survival improvement in small cell lung cancer after sequential chemotherapy with three non-cross resistant drug regimens - a pilot study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/0169-5002(91)90023-Y | |
dc.description.volume | 7 | |
dc.description.issue | 5 | |
dc.description.startingpage | 279 | |
dc.description.endingpage | 283 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |